Interleukin (IL)-23p19 inhibitors are increasingly used in immune-mediated inflammatory diseases (IMIDs), particularly inflammatory bowel disease (IBD). Almost half of patients show inadequate response, partly due to pharmacokinetic (PK) variability. However, a comprehensive overview of their PK parameters is lacking,...
I. A. Pool, Alise D. E. de Groot, R. J. Keizer et al.· Clinical Pharmacokinetics· 0 citations
Target attainment was suboptimal for most TKIs, supporting the need for TDM-guided optimisation and individualised dosing, and Associations between TKI exposure and renal, hepatic, and haematological parameters further support personalised treatment strategies.
Zaid N. Al Shirity, P. Mian, A. Dontje et al.· Clinical Pharmacokinetics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.